Skip to main content

Advertisement

SpringerLink
Log in

Stroke in 2013

Disappointments and advances in acute stroke intervention

  • Year in Review
  • Published:

From Nature Reviews Neurology

View current issue Sign up to alerts

Clinical trials in stroke intervention during the past year have yielded contrasting results. Endovascular therapies and procedures to reduce stroke risk caused by patent foramen ovale have failed to demonstrate superiority over standard medical treatments. By contrast, a trial of neuroprotection—traditionally thought to be ineffective in humans—offers hope.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Evolution of the ischaemic core over time in cynomolgus macaques with AIS caused by middle cerebral artery occlusion.

References

  1. Broderick, J. P. et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N. Engl. J. Med. 368, 893–903 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Ciccone, A. et al. Endovascular treatment for acute ischemic stroke. N. Engl. J. Med. 368, 904–913 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kidwell, C. S. et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N. Engl. J. Med. 368, 914–923 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Carroll, J. D. et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N. Engl. J. Med. 368, 1092–1100 (2013).

    Article  CAS  PubMed  Google Scholar 

  5. Meier, B. et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N. Engl. J. Med. 368, 1083–1091 (2013).

    Article  CAS  PubMed  Google Scholar 

  6. Hill, M. D. et al. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 11, 942–950 (2012).

    Article  CAS  PubMed  Google Scholar 

  7. Rha, J. H. & Saver, J. L. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 3, 967–973 (2007).

    Article  Google Scholar 

  8. Cook, D. J., Teves, L. & Tymianski, M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature 483, 213–217 (2012).

    Article  CAS  PubMed  Google Scholar 

  9. Furlan, A. J. et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N. Engl. J. Med. 366, 991–999 (2012).

    Article  CAS  PubMed  Google Scholar 

  10. O'Collins, V. E. et al. 1,026 experimental treatments in acute stroke. Ann. Neurol. 59, 467–477 (2006).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Neurosurgery, Toronto Western Hospital, 4W-435, 399 Bathurst Street, Toronto, ON M5T-2S8, Canada

    Michael Tymianski

Authors
  1. Michael Tymianski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Tymianski.

Ethics declarations

Competing interests

M. Tymianski is president of NoNO Inc., a biotechnology company founded to develop PSD95 inhibitors discovered in his research laboratory.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tymianski, M. Disappointments and advances in acute stroke intervention. Nat Rev Neurol 10, 66–68 (2014). https://doi.org/10.1038/nrneurol.2013.271

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2013.271

  • Springer Nature Limited

This article is cited by

Search

Navigation